H2 2026 Earnings
Financial report interval: 2025.12.30 - 2026.06.30
Overview: Clinuvel Pharmaceuticals(CUVL) the Revenue is 39.33 M (+1.54%), Miss estimate;the EBIT is 17.46 M (+7.85%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.04B1.54%
0.04B7.71%
-0.00B6.17%
EBITMiss expectations
0.02B7.85%
0.02B25.98%
-0.00B18.13%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf